Lionsgate Buys Contained Action Thriller Pitch

Lionsgate has acquired an untitled contained action thriller pitch from writer-directors Dan Berk and Robert Olsen, with Unknown Quantity producing.

Updated on Nov. 22, 2026 in Film — General

Bold graphic poster illustration in hot red, black, and pale grey, showing a narrow concrete corridor leading to a single red light, evoking a tense confined action thriller.
Lionsgate has acquired an untitled contained action thriller pitch from writer-directors Dan Berk and Robert Olsen, with Chris Bremner and Jeff Arkuss producing through their new company Unknown Quantity. AI Illustration. Upload story photo >

Lionsgate has acquired an untitled pitch for a contained action thriller from Dan Berk and Robert Olsen, who will write and direct the project. Chris Bremner and Jeff Arkuss will produce through their newly launched company, Unknown Quantity.

Why it matters

The deal signals continued studio interest in lower-concept, tightly staged action genre films from writer-directors with recent box-office credibility. It also marks an early project for Unknown Quantity, a production company launched earlier in 2026.

The writers' most recent comparable project, Novocaine, debuted at No. 1 at the domestic box office after its March 14, 2025 release, though Paramount, not Lionsgate, distributed it. No deal terms, budget or release window for the new thriller have been disclosed.

The players

Lionsgate

Lionsgate is a major global film and television studio headquartered in Vancouver, known for franchises and mid-budget genre films.

Unknown Quantity

Unknown Quantity is a production company launched in 2026 by producers Chris Bremner and Jeff Arkuss to develop and produce film projects.

The details

Dan Berk and Robert Olsen sold Lionsgate an untitled pitch for a contained action thriller, and they will write and direct the project. Lionsgate executive Chelsea Kujawa is overseeing the film for the studio, which has not yet assigned it a release date.

Timeline

  1. Unknown Quantity launched earlier in 2026.

  2. Novocaine was released on March 14, 2025.

Industry Dynamics

The deal follows a pattern of studios seeking contained, low-cost action originals from writers with a recent hit, as seen with Novocaine's March 2025 opening. It reflects how mid-budget genre filmmaking continues to be developed through new independent production companies rather than only through established studio units.

No release date, platform or theatrical window has been announced, so audiences cannot yet plan to see the thriller. Viewers interested in the project should expect updates on distribution only as Lionsgate sets a schedule.

The takeaway

Studio deals for original genre pitches often move from acquisition to production over long timelines, so announced projects may take years to reach audiences. Watch for casting and a release date before assuming a project's timing.

Further reading

Explore more in Film — General coverage of studio deals and original film projects.

Source note: This article includes information reported by Movieweb.